MRK--
SLS--
sls mrks phase 3 survival data blockbuster potential
🚨 $SLS — WHAT INCREDIBLE TIMING! 🚨 Same day SELLAS shares positive Phase 3 REGAL results, Merck says it's ending its BELLWAVE blood cancer program, including three Phase 3 trials! 🔥 Merck loses a major late-stage hematology asset. 🔥 GPS cuts death risk by 41%. 🔥 Median survival: 24 vs. 14.7 months. 🔥 SLS009 adds another potential blockbuster. 🔥 Merck stays focused on hematology. Could SELLAS be exactly what Merck needs to boost its blood cancer pipeline? While the leukemia parts differ and no acquisition talks are confirmed, the strategic possibilities are exciting! Big Pharma needs new drugs, and SELLAS just delivered strong Phase 3 survival data. Could the next big move be a partnership or buyout? The timing certainly fuels the speculation! 🚀💰 $SLS $MRK #BuyoutPotential
Disclaimer: The above is a summary showing certain market information. Ainvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing, All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market.Report an Issue

Comments
No comments yet